>So what follows the [big-money buyout] pattern of Sirna and Sirtris? How about Geron for embryonic stem cells?<
How about MNTA for its unique characterization technology?
Maybe Congress should give the FDA a special appropriation so the FDA itself can acquire the technology (but not the drug-development programs, obviously). I’m only half joking.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”